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Cancer cachexia is characterised by metabolic alterations leading to loss of adipose tissue and lean body mass and directly
compromises physical performance and the quality of life of cancer patients. In a murine cancer cachectic model, the effects of dietary
supplementation with a specific combination of high protein, leucine and fish oil on weight loss, muscle function and physical activity
were investigated. Male CD2F1 mice, 6–7 weeks old, were divided into body weight-matched groups: (1) control, (2) tumour-
bearing, and (3) tumour-bearing receiving experimental diets. Tumours were induced by s.c. inoculation with murine colon
adenocarcinoma (C26) cells. Food intake, body mass, tumour size and 24h-activity were monitored. Then, 20 days after tumour/
vehicle inoculation, the animals were killed and muscle function was tested ex vivo. Tumour-bearing mice showed reduced carcass,
muscle and fat mass compared with controls. EDL muscle performance and total daily activity were impaired in the tumour-bearing
mice. Addition of single nutrients resulted in no or modest effects. However, supplementation of the diet with the all-in combination
of high protein, leucine and fish oil significantly reduced loss of carcass, muscle and fat mass (loss in mass 45, 52 and 65% of TB-con,
respectively (Po0.02)) and improved muscle performance (loss of max force reduced to 55–64% of TB-con (Po0.05)). Moreover,
total daily activity normalised after intervention with the specific nutritional combination (50% of the reduction in activity of TB-con
(Po0.05)). In conclusion, a nutritional combination of high protein, leucine and fish oil reduced cachectic symptoms and improved
functional performance in cancer cachectic mice. Comparison of the nutritional combination with its individual modules revealed
additive effects of the single components provided.
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Cancer cachexia is one of the most debilitating aspects of cancer
and has been associated with increased morbidity and mortality,
reduced quality of life, impaired response to chemotherapy,
increased susceptibility to chemotherapy-induced toxicity and a
higher incidence of post-operative complications (Argiles, 2005). A
consensus on the definition for cachexia has been reached at the
4th International Conference on Cachexia at Tampa (Consensus
definition cachexia/Cachexia Conference Tampa 2007: ‘Cachexia,
also known as Wasting Disease, is a complex metabolic syndrome
associated with underlying illness and characterized by loss of
muscle with or without loss of fat mass. The prominent clinical
feature of cachexia is weight loss in adults (corrected for fluid
retention) or growth failure in children (excluding endocrine
disorders). Anorexia, inflammation, insulin resistance and in-
creased muscle protein breakdown are frequently associated with
cachexia. Cachexia is distinct from starvation, age-related loss of
muscle mass, primary depression, malabsorption and hyper-
thyroidism and is associated with increased morbidity’.) (Evans
et al, 2008). Cancer cachexia is characterised by involuntary weight
loss with a depletion of not only fat mass, but also lean body mass
due to muscle wasting. Symptoms besides weight loss are
debilitation, weakness, oedema, impaired immune response, and
a decline of motor and mental functions (Argiles, 2005).
Approximately 45% of cancer patients loose more than 10% of
their pre-diagnostic weight (Argiles, 2005). The tumour can induce
changes in protein metabolism, resembling those found in infec-
tion or injury (Argiles, 2005). These changes are characterised by a
net protein breakdown and an increased oxidation of branched-
chain amino acids (BCAAs), especially in muscle, to support
energy supply (e.g., gluconeogenesis from amino acid carbon
skeletons) and to provide amino acids for the synthesis of acute
phase proteins ((Baracos and Mackenzie, 2006; Choudry et al,
2006) for reviews). The breakdown of the host protein is partly
stimulated by inflammatory mediators (e.g., TNFa, IL-6) produced
not only by the host, but also by the tumour (Argiles, 2005).
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sWe hypothesise that nutritional support in cancer patients
should aim for a direct counteraction of the net body protein
breakdown, rather than for a mere increase in caloric intake. To
establish a net positive protein balance, protein supplementation
should be combined with specific components modifying and
mitigating both the catabolic and anabolic signals.
Fish oil derived N-3 polyunsaturated fatty acids (PUFAs)
(Colomer et al, 2007) may have anti-catabolic effects through a
reduction of the inflammatory state. The vast majority of the
clinical trials in which fish oil derived n-3 PUFAs were tested report
an increase (Wigmore et al, 1996, 2000; Barber et al, 1999, 2001;
Jatoi et al, 2004) or maintenance (Burns et al, 1999, 2004; Fearon
et al, 2003) of body weight (BW), whereas in two other clinical trials
no effect on the loss of BW was found (Gogos et al, 1998; Bruera
et al, 2003). In the latter, however, the supplementation period was
only 2 weeks (Bruera et al, 2003) and/or only a small number of
patients was included (Gogos et al, 1998). In a clinical trial in
pancreatic cancer patients, in which a fish oil-enriched product was
tested against an isocaloric/isonitrogenous placebo, no differences
between groups were found on either LBM or physical activity.
However, when compared with baseline values, total energy
expenditure, resting energy expenditure and physical activity level
increased significantly in those randomised to the n-3 enriched
supplement (Moses et al, 2004). Other studies on supplementation
with EPA or fish oil, specifically in cancer patients, showed a net
lean tissue mass gain (Fearon et al, 2003), an increase in total
resting energy expenditure and physical activity, a decreased need
for total parenteral nutrition (TPN) (Kenler et al, 1996) and an
improved quality of life (Fearon et al, 2003; Burns et al, 2004). One
study suggested improved survival (Gogos et al, 1998).
Protein synthesis cannot occur without the presence of the
building units, the amino acids. In fact, a high supply of essential
amino acids has been described to be essential for increasing
protein synthesis (Rooyackers and Nair, 1997), indicating that not
only the quantity, but also the quality of the amino acid supply is
vital. Therefore, the protein fraction supplemented has to be rich
in essential amino acids.
BCAAs and especially leucine are known to control skeletal
muscle protein metabolism (Kobayashi et al, 2006) by stimulating
protein synthesis and inhibiting protein breakdown. Prospective
caloric- and nitrogen-controlled trials of BCAA supplementation
through TPN) in septic patients indeed resulted in an improve-
ment of pre-albumin levels and a decreased overall mortality
(Jimenez Jimenez et al, 1991; Garcia-de-Lorenzo et al, 1997).
Anthony and co-workers showed in various rat models that
leucine enhances protein synthesis in skeletal muscle through
both insulin-dependent and -independent mechanisms (Anthony
et al, 2002a,b). In tumour-bearing rats a diet supplemented
with 3% leucine has been reported to reduce loss of lean body
mass, gastrocnemius muscle mass and myosin content, when
compared to an isonitrogenous and isocaloric control diet
(Gomes-Marcondes et al, 2003). These data are supported by the
observation that leucine increased protein synthesis in pregnant
tumour-bearing rats, possibly resulting from changes in the
ubiquitin–proteasome system (Ventrucci et al, 2004). In humans,
leucine supplementation resulted in an improved muscle protein
synthesis in young (Koopman et al, 2005) and elderly volunteers
(Katsanos et al, 2006; Koopman et al, 2006; Rieu et al, 2006). There
are two clinical trials in cancer patients that studied oral BCAA
supplementation after surgical removal of the tumour. These
studies reported a shorter hospital stay, a better performance
status at 3 months and an increased body mass at 1 year following
surgery (Surgery, 1997; Meng et al, 1999). BCAAs have also been
supplemented in the presence of the tumour: patients undergoing
chemotherapy received oral BCAA supplementation up to 1 year
after the start of chemotherapy, resulting in a lower overall
morbidity, an improved nutritional status and a better quality of
life (Poon et al, 2004).
We hypothesise that nutritional support in cancer patients is
most effective if aimed simultaneously for a variety of parameters
involved in cachexia. Therefore, we studied, in a cancer cachectic
murine model, the effect of a combined nutritional supplementa-
tion high in protein, rich in leucine and EAA and fish oil compared
with single-compound supplementation, on cancer-induced weight
loss. Next, also the effects on clinically relevant functional
readouts, such as muscle function and physical activity were
investigated. To this end the colon 26 adenocarcinoma bearing the
cachectic mouse model was used, which has repeatedly shown the
loss of muscle mass and muscle function without significant effects
on food intake (Tanaka et al, 1990; Diffee et al, 2002; Gorselink
et al, 2006), which makes it a suitable model to study the effect of
specific nutritional ingredients on cancer cachexia.
MATERIALS AND METHODS
Animals
Male CD2F1 mice at 6–7 weeks, (BALB/c DBA/2, Harlan/Charles
River, the Netherlands) were individually housed in a climate-
controlled room (12:12 dark–light cycle with a constant room
temperature of 21±11C). After acclimatisation for 1 week mice
were divided into weight-matched groups: (1) control receiving
control chow, (2) tumour-bearing receiving control chow, and (3)
tumour-bearing receiving experimental diets. Data shown are
derived from the combination of several experimental runs with
identical animal characteristics and experimental procedures
(unless stated otherwise) and differ only in the experimental diets
used. All experimental procedures were approved by the Animal
Ethical Committee (DEC consult, Bilthoven, The Netherlands) and
complied with the principles of good laboratory animal care.
Experimental diets (categories A and B experiments)
Experiments are divided in: (A) experiments designed to test the
effect of single or combined nutritional components (addition of
high protein (hpr), leucine (leu), fish oil (fo)), added to the
background diet (AIN93-M) and supplied as pellets; (B) experi-
ments designed to test the effect of a complex nutritional
combination that resembles the composition of the new generation
FortiCare (Nutricia Advanced Medical Nutrition).
The AIN93-M control diet in the category A experiments
contained per kg feed: 126g protein (100% casein), 727g
carbohydrates and 40g fat (100% soy oil) (Research Diet Services,
Wijk bij Duurstede, the Netherlands). Experimental diets in this
category were adjusted to control diets by partly replacing
the carbohydrates and/or soy oil by protein and leucine (151g
casein/kg and 16g leucine/kg feed; TBþhprþleu), high protein
and fish oil (151g casein/kg and 22g fish oil/kg feed; TBþfoþ
hrp), or high protein and leucine and fish oil (151g casein/kg, 16g
leucine/kg and 22g fish oil/kg food; TBþfoþhprþleu). The 22g
of fish oil contained 6.9g EPA and 3.1g DHA in a ratio of 2.2:1. In
summary, in experiment A the following diets and interventions
were compared: (1) no tumour, AIN93-M fed (Con); (2) tumour-
inoculated AIN93-M fed (TB-con); (3) tumour-inoculated fed
AIN93-M with additional protein and leucine (TBþhprþleu); (4)
tumour-inoculated fed AIN93-M with additional fish oil (TBþfo);
(5) tumour-inoculated fed AIN93-M with additional fish oil and
protein (TBþfoþhrp); (6) tumour-inoculated fed AIN93-M with
additional fish oil, high protein and leucine (TBþfoþhprþleu).
In the category B experiment, the control diet was a more
humanised diet, isocaloric and isonitrogenous to the control diet
in the A category of experiments, and contained per kg feed 126g
protein (casein), 53g fat (corn oil), and 699g carbohydrates. The
isocaloric experimental diet (further referred to as Specific
Nutritional Composition; SNC) contained per kg feed: 210g
protein (189g intact protein of which 68% casein and 32% whey
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22.2g fish oil (providing 6.9g EPA and 3.1g DHA)), 561g
carbohydrates, 18g galacto-oligosaccharides and 2g fructo-oligo-
saccharides. In experiment B, diets were supplied as dough for
product technical reasons.
Tumour model
Murine C-26 adenocarcinoma cells were cultured in vitro with
RPMI-1640 supplemented with 5% fetal calf serum and 1%
penicillin–streptomycin (Tanaka et al, 1990). Tumour cells were
trypsinised in a sub-confluent state and, after washing, suspended
in Hanks’ balanced salt solution (HBSS) at a concentration of
2.5 10
6 cellsml
 1. Under general anaesthesia (isoflurane/
N2O/O2), tumour cells (5 10
5 cells in 0.2ml) were inoculated
subcutaneously into the right inguinal flank of the mice. Control
(C) animals received a sham injection with 0.2ml HBSS.
Experimental protocol
Following inoculation of tumour cells or HBSS, body mass, food
intake and tumour size (length and width) were measured three
times a week. Only in the category B experiment, daily activity in
the home cage was monitored. In all experiments, animals were
anaesthetised and weighted at day 20 after tumour inoculation.
Skeletal muscles (e.g., m. Tibialis Anterior (mTA), m. Gastro-
cnemius (mG), m. Extensor Digitorum Longus (mEDL) and
M Soleus (mS)), the tumour, spleen, kidneys, liver, epididymal
fat, thymus, lungs and heart were dissected and weighed. Carcass
mass was calculated by subtracting tumour mass from body mass.
In addition, muscle function was tested ex vivo in the category B
experiment.
Assessment of daily activity
Physical activity was monitored continuously (24h) during the
20-day study period starting at day 2, using activity sensors (dual
technology detector DUO 240, Visonic; adapted by R Visser, NIN,
Amsterdam, The Netherlands) that translated individual changes
in the infrared pattern caused by movements of the animals into
arbitrary activity counts. Sensors were mounted above the home
cages and were connected through input ports and interface to a
computer equipped with MED-PC IV software for data collection
(MED associates, St Albans, VT, USA). Activity was expressed in
counts per hour (both for the total 24-h period, the dark period
(active period) and the light period (inactive period)). Activity was
calculated for each mouse separately and was expressed relative to
its own total activity on day 2, to correct for differences in the
individual sensitivity of sensors. The activities of two subsequent
days were averaged, to dampen the day to day variability. To
determine changes in the activity pattern throughout the experi-
ment, hourly and dark–light activity were expressed as percentage
of total daily activity and translated into an actogram.
Assessment of muscular functionality
Contractile characteristics of the right EDL muscle were assessed
ex vivo, as described previously (Gorselink et al, 2006). Briefly,
muscles were allowed to stabilise in the organ bath for 30min, after
which optimal stimulation current and strength were determined.
Then force-frequency characteristics (10–167Hz, 250ms) were
determined and after replenishing the organ buffer and a resting
period of 5min, muscles were subjected to an exercise protocol
(83Hz, 250ms every 1000ms). This protocol represents a
moderate load, comparable with normal daily activity. At the
frequency used, complete tetanus of the muscle is reached.
Isometric force signals of the force–frequency curve were analysed
for maximal and total force and for maximal contraction and
relaxation velocity.
Statistics
All data are expressed as means±s.e.m. Statistical analyses were
performed using SPSS 15.0 (SPSS Benelux, Gorinchem, the
Netherlands). In experiment A different batches of animals were
used, therefore, for all parameters it was defined that combination
of data was allowed if no interaction between groups and
experiments were present. Body composition data, tumour and
organ masses on day 20 were compared between groups with
analysis of variance (ANOVA) and post hoc LSD. Differences were
considered significant at a P-value below a/k; in which a¼10%
and k¼amount of comparisons. For experiment A the P-value had
to be below 0.02; for experiment B the P-value had to be below
0.05. Data on food intake, body weight, daily activity, and muscle
function that were monitored during the 20 days after inoculation
were analysed by repeated measures ANOVA. To further
discriminate the differences between groups, the differences or
deltas from the first measurement in the range were calculated.
These deltas were compared between groups using ANOVA, with
post hoc LSD for pairwise comparison between groups. For skeletal
muscle function, data of first measurement at day 20 were not
similar between groups, therefore further discrimination was
performed in a per point analysis ANOVA. Differences were
considered significant at a two-tailed Po0.05.
RESULTS
Effects of single vs combined nutritional components on
different parameters of cachexia
Compared with control mice (Con), carcass and body weight were
significantly lower in tumour-bearing control mice (TB-con) on
day 20 after tumour inoculation (Table 1A). For all parameters
measured there was no group times experiment interaction. The
loss of body weight in TB-con mice was derived from both loss of
muscle mass and fat mass (e.g., epididymal fat) (Figure 1A and B).
No differences in food intake were present between groups for
complete curves. When analysed separately per day, at day 20, Con
was significantly different from TB-con. None of the tumour-
bearing groups were significantly different from each other
(Table 1B). Addition of extra protein and leucine (TBþhprþleu)
or fish oil (TBþfo) did not change body weight compared with
TB-con (Table 1A). However, addition of fish oil to extra protein
(TBþfoþhpr) or fish oil to extra protein and leucine
(TBþfoþhprþleu), resulted in a significant higher fat mass
compared with TB-con (Figure 1B). Only the supplementation of
the diet with the all-in combination of high protein, leucine and
fish oil (TBþfoþhprþleu) resulted in a significant improvement
of body and carcass weight (Table 1A), and of muscle (mTA) and
fat (epididymal) mass, compared with TB-con mice (Figure 1).
Additive effects of the combination of leucine and high protein
were found for muscle mass of the mTA in the presence of fish oil.
Addition of each component increased muscle mass stepwise
(Figure 1A).
Effect of a specific nutritional combination on parameters
of cachexia
Body and carcass weight were significantly lower in tumour-
bearing mice (TB-CON) compared with control mice (CON) on
day 20 (Table 2A). The difference in body weight change already
being significant at day 15 after tumour inoculation (Table 2C).
Again, a significant lower fat mass (epididymal fat) and muscle
mass was observed in the TB-CON mice (Table 2B). Food intake
Dietary supplementation with a specific combination
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bearing mice receiving the Specific Nutritional Combination
(TB-SNC group) had a higher body weight, and delta body
weight compared with TB-CON mice. The attenuation of body
weight loss in the TB-SNC mice coincided with a reduction of fat
loss and a reduction in muscle wasting (mTA, mG, and mS)
(Table 2B).
Organ (wet) mass of kidney, liver, thymus and heart either
decreased with increased cachexia or showed no change (Table 3).
Nutritional supplementation resulting in increased carcass weight
partly compensated the weight loss. For experiment B the data for
organ masses (in percentage of control (CON) ±s.e.m.) were:
kidney: TB-CON: 81%±2; TB-SNC: 91%±2, liver TB-CON:
88%±2; TB-SNC: 92%±3, thymus TB-CON: 46%±4; TB-SNC:
55%±4, heart TB-CON: 86%±2; TB-SNC: 88%±2, and lung:
TB-CON: 98%±2; TB-SNC: 103%±3. Tumour mass was not
increased by any of the nutritional supplementations (Tables 1
and 2).
Ex vivo muscle function (category B experiment)
Force–frequency characteristics (10–167Hz, 250ms) were deter-
mined ex vivo in mEDL. Maximal force, maximal contraction
velocity and maximal relaxation velocity were significantly
different in TB-CON when compared with CON and TB-SNC
(Figure 2A, B and C). When these parameters were corrected for
muscle mass, overall curve positions were maintained. Significant
differences, however, remained only between CON and TB-CON.
To further investigate muscle mass-independent changes in muscle
function the time needed for a contraction (CT90) was determined.
CT90 was defined as the time needed to go from 10 to 90% of
maximal contraction force, at frequencies at which tetanus was
obtained. CT90 was significantly different between TB-SNC and
TB-CON at lower frequencies at which total tetanus could be
obtained (83 and 100Hz). These data suggest that at frequencies
(83–100Hz) relevant for efficient physical performance (tetanus
present), besides muscle mass-dependent changes, also muscle
mass-independent changes had occurred that were corrected by
specific nutritional intervention. Therefore, an exercise protocol of
100 repeated pulses was applied at 83Hz. Again, CON and TB-SNC
were significantly different from TB-CON during the whole
exercise protocol for maximal contraction force (Figure 3A) and
maximal contraction velocity (Figure 3C). When maximal
contraction force was corrected for muscle mass (Figure 3B) curve
positions remained, with only significant differences between CON
and TB-CON. Maximal contraction velocity of the TB-SNC group;
however, was still significantly different from TB-CON when
corrected for muscle mass in the first repeats of the exercise (o10
repeats) (Figure 3D).
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Figure 1 Differences in muscle and fat mass at day 20 after interventions
with single or combined nutritional components (Experiment A). (A)
muscle Tibialis Anterior mass and (B) Epididymal fat mass. Con¼mice
receiving control diet A (AIN93), TB-con¼tumour-bearing mice receiving
control diet A (AIN93), hpr¼high protein, leu¼leucine, fo¼fish oil. Data
are means±s.e.m.; *significantly different from TB-con (Po0.02) (k¼5,
a¼10%) (For more details about statistics, see the Materials and Methods
section).
Table 1 Effects of single or combined nutritional components on body composition, and food intake (experiment A)
(A) Carcass, tumour and fat masses at section (grams at day 20)
Treatment N Carcass weight P Body weight P Tumour weight P
Con 40 24.4±0.3 0.000* 24.4±0.3 0.001* 0.0±0.0 0.0000*
TB-Con 40 20.7±0.4 — 22.8±0.4 — 2.2±0.1 —
TB-hpr+leu 10 20.0±0.6 0.807 21.8±0.6 0.992 1.8±0.1 0.1472
TB+fo 10 20.9±0.8 0.226 23.0±0.8 0.238 2.1±0.1 0.6854
TB+fo+hpr 10 22.2±0.8 0.034 24.2±0.7 0.038 2.0±0.1 0.5053
TB+fo+hpr+leu 22 22.7±0.6 0.010* 24.4±0.5 0.019* 1.7±0.1 0.0659
(B) Food intake (gram per day)
Treatment N Day 1 Day 7 Day 14 Day 17 Day 19 Day 20
Con 40 4.5 3.8 4.0 3.8 3.7 3.6*
TB-con 40 4.2 3.9 3.8 3.8 3.5 2.9
TB-hpr+leu 10 4.7 3.8 4.0 3.1 3.7 2.9
TB+fo 10 5.4 3.9 4.1 4.0 3.1 2.3
TB+fo+hpr 10 4.4 3.9 3.9 3.7 3.3 2.6
TB+fo+hpr+leu 22 4.4 3.5 4.1 3.5 3.4 3.0
Con¼mice receiving control diet A (AIN93), TB-con¼tumour-bearing mice receiving control diet A (AIN93), hpr¼high protein, leu¼leucine, fo¼fish oil. Data as
means±s.e.m.: *significantly different from TB-con (Po0.02, k¼5, a¼10%) (For more details about statistics, see the Materials and Methods section).
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Total daily activity showed a significant interaction between time
and group (Po0.01; RM-ANOVA) over the total period (2–19
days). Activity levels in TB-CON mice were significantly lower than
in control mice on days 10–11 (Po0.05), and from day 16
onwards (Po0.01). The TB-SNC animals did not differ signifi-
cantly from the control animals in their total activity throughout
the experiment, whereas their activity was significantly higher at
days 18–19 compared with TB-CON mice (Po0.05) (Figure 4A).
These differences in total activity resulted from significant changes
during their active period (i.e., dark period) (Figure 4B).
Throughout the dark period, TB-CON mice were significantly less
active than controls on days 16–17 and 18–19 (Po0.01), resulting
in a drastic decrease in overall activity in the TB-CON mice. The
TB-SNC mice were less active than control mice during the dark on
day 18–19 (Po0.05), but more active than TB-CON mice on those
days (Po0.05).
Besides a reduction in daily activity level of TB-CON mice, a
clear shift in daily activity pattern was observed, that is, from dark
to light, both in tumour-bearing controls and in TB-SNC animals
on days 18–19 (Figure 4C). To focus on possible shifts in daily
activity pattern, hourly activity pattern during the day was
expressed as a percentage of the total (100%) daily activity on
Table 2 Effects of the specific nutritional combination (SNC) on cachexia parameters (experiment B)
(A) Body, tumour and carcass weight at section (g at day 20)
Treatment N BW Delta BW TW CW Delta CW
CON 10 28.0±0.7* 5.3±0.5* 0.0±0.0* 28.0±0.7* 5.3±0.5*
TB-CON 17 20.8±0.5  0.7±0.4 2.1±0.1 18.7±0.4  2.8±0.4
TB-SNC 18 23.1±0.6* 0.9±0.6* 1.7±0.1* 21.4±0.6*  0.7±0.7*
(B) Organ weights at section (mg at day 20)
Treatment N Epididymal fat mTA mG mEDL mS
CON 10 443±37* 44.5±1.3* 141±4* 9.2±1.1 6.7±0.5*
TB-CON 17 87±18 33.4±0.9 108±2 7.8±0.2 5.3±0.2
TB-SNC 18 189±20* 38.1±0.9* 118±3* 8.3±0.5 5.7±0.2*
(C) Change in BW in time
Change in BW (change in g: days 0–20 when compared to day 1)
Treatment N 0 6 10 15 20
CON 10 1.0±0.3 3.6±0.4 4.3±0.7 5.5±1.0* 6.3±1.4
#
TB-CON 17 0.6±0.3 2.7±0.3 3.3±0.3 3.7±0.4  0.1±0.5
TB-SNC 18 0.9±0.2 3.4±0.3 4.4±0.4 4.6±0.4 1.8±0.6
#
(D) Food intake in time
Food intake per day (g)
Treatment N 81 3 1 71 9
CON 10 4.4±0.2 4.3±0.2 4.4±0.3 3.5±0.6
TB-CON 17 4.0±0.2 4.1±0.1 3.7±0.3 3.5±0.5
TB-SNC 18 4.2±0.1 4.5±0.2 4.8±0.3 4.4±0.4
CON¼mice receiving control diet B, TB-CON¼tumour-bearing mice receiving control diet B, TB-SNC¼tumour-bearing mice receiving the specific nutritional combination.
BW¼body weight; CW¼carcass weight; delta BW¼BW day 20minus BW day 0, delta CW¼CW day 20minus CW day 0, TW¼tumour weight, mTA¼muscle Tibialis
Anterior, mG¼muscle Gastrocnemius, mEDL¼muscle Extensor Digitorum Longus, mS¼muscle Soleus. Data as means±s.e.m.; *significantly different from TB-CON
(Po0.05, k¼2, a¼10%)
#significantly different from TB-CON for the whole curve (Po0.05, k¼2, a¼10%) (For more details about statistics, see the Materials and
Methods section).
Table 3 Effects of the specific nutritional combination (SNC) on cancer cachexia-induced organ mass changes (experiment B)
Organ masses at section (grams at day 20)
Treatment N Kidney P Liver P Thymus P
CON 10 422±10.9 0.000* 1196.8±123.3 0.002* 40.3±10.9 0.0000*
TB-CON 17 342±8.0 — 1050.1±92.3 18.5±6.9
TB-SNC 18 385±9.3 0.001* 1101.1±125.5 0.191 22.3±7.3 0.01749
Treatment N Heart P Lung P
CON 10 150.9±3.1 0.000* 161.9±4.4 0.715
TB-CON 17 129.4±2.7 — 159.3±3.7 —
TB-SNC 18 133.6±3.1 0.290 167.0±4.8 0.196
CON¼mice receiving control diet B, TB-CON¼tumour-bearing mice receiving control diet B, TB-SNC¼tumour-bearing mice receiving the specific nutritional combination.
Data as means±s.e.m.; *significantly different from TB-CON (Po0.05, k¼2, a¼10%) (For more details about statistics, see the Materials and Methods section).
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Figure 2 The effect of the specific nutritional combination on skeletal muscle function: force frequency curve (ex vivo experiment B). CON¼mice
receiving control diet B, TB-CON¼tumour-bearing mice receiving control diet B, TB-SNC¼tumour-bearing mice receiving the specific nutritional
combination. Data are means±s.e.m.; data were significantly different from TB-CON when Po0.05 (k¼2, a¼10%). (A) Maximal contraction force
(complete curves significantly different from each other Po0.01). (B) Maximal contraction velocity (complete curves significantly different from each other
Po0.01). (C) Maximal relaxation velocity (complete curves significantly different from each other Po0.01). (D) CT90: time needed for contraction from
10 to 90% of maximal force (CON significantly different from TB-CON for range 83–176Hz; TB-SNC significantly different from TB-CON for range
83–100Hz).
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corrected for the graduate decline in activity for the tumour-
bearing groups). At baseline (days 2–3) all groups showed
comparable day/night rhythms. Animals were active during the
dark and had an inactive period during the light. A relative shift
towards increased activity during the light period is observed
in the TB-CON group from day 16, which occurs less or delayed
in the TB-SNC group.
DISCUSSION
In this study, the effect of a nutritional supplementation with
single vs multiple components on body composition in the murine
C26 carcinoma model was investigated. In contrast to supple-
mentation of the single ingredients, the combination demonstrated
a significant effect on the body composition. In addition, the
specific nutritional combination also improved muscle function.
Moreover, activity patterns as well as overall daily activity
improved, probably as a consequence of improved body composi-
tion and muscle function. This clearly supports the added value of
a multi target approach, in which catabolism (both protein and fat)
is targeted through a reduction of inflammation through the
addition of fish oil; whereas anabolism is specifically targeted by
protein synthesis through the supplementation of high protein and
leucine. The effects on body composition and performance are
highly relevant to the clinical situation, because muscle function
and daily activity are important contributors to the quality of life
of the cancer patient (Morrow et al, 2002). Moreover, from a
retrospective study in 1555 patients with gastrointestinal carcino-
mas it was concluded that patients with weight loss had a poorer
outcome from treatment than patients without weight loss. This
difference contributed to the fact that the patients with weight loss
received significantly less chemotherapy and experienced more
toxicity from the treatment (Andreyev et al, 1998). These findings
indicate that maintenance of body composition may beneficially
contribute to compliance of the patient to the therapy.
The data focus on the specific needs of the cancer patient and
the possible role for nutrition in improving or preventing cachexia
characteristics. The data show the effects of different isocaloric
nutritional interventions with single ingredients or combinations
in the C26 murine model of cancer-induced cachexia. There were
no significant differences on food intake between groups on
complete curves nor on analysis per day up to day 19. These data
confirm earlier findings that for cachexia, validated C26 adeno-
carcinoma mouse model can be used as a cachectic non-anorectic
model (Tanaka et al, 1990; Diffee et al, 2002; Gorselink et al, 2006)
The observation, however, that in experiment A, food intake of
Con is significantly higher than that of TB mice on day 20
specifically indicates that if tumour growth would continue for a
few days more, the tumour-bearing animals would likely become
anorectic. The differences in cachectic parameters between control
and tumour-bearing mice 20 days after tumour inoculation, were
comparable in magnitude to those described in other studies also
using the C26 adenocarcinoma mouse model (Lazarus et al, 1996;
Matsumoto et al, 1999; Samuels et al, 2000; Fujimoto-Ouchi et al,
2006; Gorselink et al, 2006).
None of the single components had direct effects. Only the
combination of fish oil and high protein increased fat mass. Fat
mass has been suggested to be important in survival of the patient
(Kalantar-Zadeh et al, 2007) whereas muscle mass has been
implicated to contribute specifically to the quality of life of the
patient (Muscaritoli et al, 2004). The data on mTA muscle mass
show that at the tested concentration the combination of all
components, that is, fish oil, high protein and leucine were needed
for a significant effect on muscle mass (Figure 1). Moreover, the
results are in line with the hypothesis that next to an increase in
anabolic responses, protein catabolism has to be decreased by
reduction of inflammation to reach a positive effect on muscle
protein mass in a cancer cachectic state. There is growing support
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sthat the inflammatory response to a tumour attributes consider-
ably to the progression towards cachexia. It has also been
suggested that the increase in catabolic vs anabolic processes
contributes to the failure to accumulate lean body mass even when
nutritional intake is normal (Argiles, 2005). Clinical data from
different cachectic patient groups (Wigmore et al, 1996, 2000;
Barber et al, 1999, 2001; Jatoi et al, 2004) suggest that fish oil might
reduce catabolism and weight loss. Fish oil probably not only
attenuates the tumour-induced inflammatory response, but also
normalises the insulin resistance present in the cachectic state
(Wigmore et al, 1996, 2000; Barber et al, 1999, 2001; Jatoi et al,
2004). Prolongation of survival has been reported in a mixed group
of advanced cancer patients supplemented with n-3 fatty acids and
vitamin E (Gogos et al, 1998) which might also result from
immune-modulation. The suggestion that in cachectic patients fish
oil might contribute to the maintenance of body composition by a
reduction of inflammatory responses, is supported by our data.
High protein with leucine (hprþleu), did not result in significant
changes in mTA mass. However, when fish oil was added, the
combination of high protein and leucine (foþhprþleu) con-
tributed to a significant weight gain of mTA. Therefore, it is
hypothesised that reduction of the inflammatory state by fish oil
improved the sensitivity of the animals to anabolic stimuli like
leucine and high protein, resulting in improved maintenance of
muscle protein mass.
Results from in vivo studies suggest that BCAAs and especially
leucine regulate skeletal muscle protein metabolism (Kobayashi
et al, 2006). This signal is related to activation of the mTOR
pathway (Kimball and Jefferson, 2006). In healthy volunteers,
leucine has been reported to provide a signal for stimulation of
muscle protein synthesis and to possibly decrease muscle protein
breakdown (Rennie et al, 2006). In healthy individuals this signal
is likely to be short-lived due to the ‘muscle-full phenomenon’
induced by normal nutritional intake and homeostatic control
mechanisms (Rennie et al, 2006). In contrast, long lasting effects of
BCAA supplementation were reported in patients with a metabolic
or nutritional deficiency like in septic or cancer patients. In these
patient groups BCAA supplementation was reported to result in
positive effects on albumin status, quality of life and overall
survival (Jimenez Jimenez et al, 1991; Garcia-de-Lorenzo et al,
1997; Surgery, 1997; Meng et al, 1999; Poon et al, 2004). Moreover,
it has been reported that protein synthesis can only be stimulated
in the presence of a high supply of balanced amounts of essential
amino acids (Rooyackers and Nair, 1997). Altogether, these studies
suggest that a combination of high protein and BCAA supple-
mentation might result in improved protein metabolism, resulting
in muscle mass gain, which could contribute to a lower morbidity
and a higher quality of life. Our data indeed suggest that
both leucine and high protein supplementation contribute to the
cumulative effect on muscle mass maintenance, reached by the
total nutritional combination (Figure 1 and Table 1).
Combination of supplementation of high protein, leucine and
fish oil resulted in a surplus value with respect to a broad spectrum
of parameters characterising cachexia. The group in which all
nutritional components were combined (TBþfoþhprþleu mice)
was the only group that showed significant differences vs TB on all
read-out parameters of cachexia (e.g., weights of body, carcass,
muscles and fat (see Table 1)). The suggested additive effects of
single nutritional components to the total combination are best
illustrated by the data on tibialis muscle mass (mTA, Figure 1).
These data clearly indicate a surplus value of a multi-nutritional
component approach. We suggest that the observed additive
effects originate from presumed differences in mechanistic targets
of these components, that is, (1) stimulation of anabolic signals by
supplementation of building blocks (essential amino acids) and by
stimulation of mTOR (leucine), (2) reduction of protein catabolism
by the reduction of inflammatory and hormonal responses (fish
oil) and downregulation of the signalling pathway leading to
protein breakdown (leucine), and the possible interaction(s)
between these mechanisms. The second experiment confirmed
the efficacy of the nutritional combination on body composition
maintenance. Moreover, in this experiment the combination of
ingredients also improved parameters reflecting physical per-
formance like muscle function and daily activity patterns.
Organ (wet) mass of kidney, liver, intestine, thymus and heart
were unaffected or decreased with increased cachexia. Nutritional
supplementation resulting in increased carcass weight had no
effect or partly normalised the loss in organ mass. Next to that,
none of the selected ingredients increased tumour size. The
complete nutritional combination showed a reduction in tumour
size in experiment B.
We found no effect of single nutrients or their combination on
food intake in the present study. Clinical data indicate that BCAA
supplementation reduces the incidence of anorexia in cancer and
malnourished patients and in patients with liver cirrhosis
(Cangiano et al, 1996; Hiroshige et al, 2001; Marchesini et al,
2003; Laviano et al, 2005, 2006; Biolo et al, 2006). In a placebo-
controlled multi-center trial in cirrhotic patients (n¼174), 1 year
supplementation with BCAA resulted in a decreased prevalence of
anorexia from 52 to 25%, whereas anorexia prevalence remained
unchanged in the control group (Marchesini et al, 2003). The
incidence of anorexia also decreased in the BCAA supplemented
group, whereas it did not change in the placebo group in a study in
cachectic cancer patients supplemented with 14.4g/day BCAA
(7.1g leucine) (Cangiano et al, 1996). Moreover, caloric intake in
the BCAA group increased. Cota et al (2006) found contradictory
results in vivo and reported an anorectic effect of Leucine after
central administration in healthy rats. Several explanations were
given by Laviano et al (2006) for this discrepancy supported by
results from clinical trials. First, Cota et al (2006) used healthy rats
of normal weights, whereas Laviano et al (2006) performed their
study in anorectic weight-losing cancer patients, aiming to
stimulate muscle weight gain in these patients. Second, leucine
may exert a different effect when supplemented balanced with
other amino acids through the oral route compared with injection
directly into the central nervous system. The fact that our data in
the C26 mice model revealed no effect of leucine supplementation
on food intake may be related to the absence of anorexia in our
cachectic model setup.
C26-tumour inoculation induced a loss of muscle function, as
reported previously (Gorselink et al, 2006). A large part of the
reduction of muscle function was explained by a reduction in
muscle mass. These findings are in accordance with clinical data.
Gogos et al (1998) reported a significantly higher Karnofsky
performance status in malnourished patients supplemented for 40
days with 18g of n-3 PUFA (3g EPA and 2g DHA) compared with
placebo. These data suggest that improvement of physical activity
may occur even before a significant weight gain is achieved. This
may indicate that for maintaining normal life activities, preventive
treatment to reduce muscle wasting is recommended. In our
experimental setup, all tumour-induced muscle mass-dependent
decreases in muscle function could be significantly restored by
supplementation with the specific nutritional combination. These
data are supported by clinical trial data of Barber et al (2001)
reporting an improved functional performance after 3 and 7 weeks
of supplementation with 2.2g EPAþ0.96g DHA in unresectable
pancreatic cancer patients. The improved physical performance
coincided with increased BW and appetite . Next to muscle mass-
dependent changes in muscle function, as described by Weber et al
(2008), also muscle mass-independent loss of function is suggested
by presented data (Figures 2D and 3D). A tumour-related, muscle
mass-independent decrease in muscle function has not been
described before. Weber et al (2008) described in humans that
cachexia is associated with a loss of muscle volume, but not of
functionality. It might be that the technique used in this study is
more accurate because muscles can be weighed instead of being
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Because the largest part of function loss is in muscle mass
dependent, the muscle mass independent changes might get lost in
the noise of variation of the data. This compromised muscle
function became especially manifest in the maximal contraction
velocity after exercise of moderate strength (Figure 3C). The
muscle mass-independent decrease in muscle function could also
be partly restored by supplementation with the specific nutritional
combination (TB-SNC). These results indicate that the nutritional
combination restores both muscle mass-dependent and muscle
mass-independent decreases in muscle function.
Asthenia, resulting from cancer cachexia, leads to a reduced
daily activity. Indeed, in the presence of a tumour, daily activity
levels of mice decreased over time which is in line with clinical
reports of cancer patients (Mormont and Levi, 1997; Mormont
et al, 2000). It is not clear what mechanism induces the reduction
in activity in cachectic cancer patients. Reduced muscle mass and
decreased muscle force may contribute to the deterioration in
activity. In addition, the tumour-induced inflammatory response
might further reduce the daily activity. Physical activity is a major
determinant of quality of life (Moses et al, 2004). The complete
nutritional combination tested maintained activity compared with
TB-CON mice. This effect may be directly related to the better
maintained physical performance (improved muscle mass and
function). The influence of the nutritional combination on other
factors involved in physical performance, however, would need
further examination.
Chevalier et al (2003) reported that patients with advanced
colorectal cancer showed less contrast between day time and night
time activity (nocturnal sleep) . Individual activity patterns have
even been suggested to be predictive of the patients’ survival,
tumour response and quality of life (Mormont and Levi, 1997;
Mormont et al, 2000). The possibility of a tumour-induced
disturbance in diurnal activity patterns is supported by our data,
indicating a tumour-related shift in activity from the dark to the
light period. The specific nutritional combination tested shows a
clear trend to reduce this effect. Normal sleep patterns are critically
dependent on the circadian release of melatonin from the pineal
gland. DHA-enriched formulas have been reported to normalise
melatonin secretion in (n-3)-deficient rats (Zaouali-Ajina et al,
1999), this might also be an explanation for the results obtained in
our experiments.
Further studies in patients are needed to confirm the anti-
cachectic properties of a nutritional supplement containing at least
leucine-enriched high protein and fish oil. Also the mechanistic
effects of the nutritional combination on inflammatory processes
warrant further research. When anorexia is present in this patient
group, the use of a high caloric supplement seems valid. In such a
setup, the effect of BCAAs in the nutritional combination on both
anorexia and cachectic parameters could be evaluated. Moreover,
based on the results from this study it is clear that more attention
should be paid to prevention of cachexia to maintain quality of life
for the patient.
In conclusion, this specific nutritional combination of high
protein, leucine and fish oil improved the cachectic outcome of
mice inoculated with the C26 adenocarcinoma cell line. The
carcass, fat and muscle mass increased and the muscle function
and daily activity improved when compared with tumour-bearing
mice on the control diet. These data show that single ingredient
interventions have limited value, and support the need for a
balanced combination of different ingredients to enable a multi-
targeted intervention to achieve beneficial effects in the complex
conditions of cancer cachexia, as reflected in changes of body
composition, muscle functionality and daily activity. The findings
are clinically highly relevant, because muscle function and daily
activity contribute to a great extent to the quality of life of the
cancer patient (Morrow et al, 2002). In addition, an improved
condition of a patient, as reflected in body composition and
physical performance, contribute to compliance of the patient to
the anti-cancer therapy (Andreyev et al, 1998).
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